Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1 Bridge Plaza, Suite 275 FORT LEE NJ 07024 |
Tel: | N/A |
Website: | https://nuvectis.com |
IR: | See website |
Key People | ||
Ron E. Bentsur Chairman of the Board, President, Chief Executive Officer, Co-Founder | Shay Shemesh Co-Founder, Executive Vice President, Chief Development and Operations Officer | Enrique Poradosu Executive Vice President, Chief Scientific and Business Office, Co-Founder | Michael Carson Vice President - Finance |
Business Overview |
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. |
Financial Overview |
For the three months ended 31 March 2024, Nuvectis Pharma Inc revenues was not reported. Net loss increased 3% to $4.2M. Higher net loss reflects Labor & Related Expenses in increase of 14% to $1.5M (expense), RESEARCH AND DEVELOPMENT - Balanci increase of 11% to $1.1M (expense), GENERAL AND ADMINISTRATIVE - Balancin increase of 1% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.27 to -$0.25. |